Why the study?
Percutaneous left atrial closure interventions may be complicated by thromboembolic events, the underlying mechanisms are not fully understood, and optimal post-procedural antithrombotic management remains under investigation.
Does oral anticoagulation therapy prevent device-related thrombus and thromboembolic complications better than antiplatelet therapy in patients undergoing percutaneous left atrial interventions?
Does oral anticoagulation therapy prevent device-related thrombus and thromboembolic complications better than antiplatelet therapy in patients undergoing percutaneous left atrial interventions?
Biomarker profiles suggest that oral anticoagulation may be more appropriate than antiplatelet therapy following percutaneous left atrial device implantation to prevent device-related thrombosis.
Answers are grounded in this paper and cite their sources.
May warrant closer post-procedural monitoring after device closure; leaves open optimal antithrombotic strategies in observational data.
Atrial septal defect, persistent foramen ovale and the left atrial appendage are nowadays often percutaneously closed with implantable devices. These interventions may be complicated by thromboembolic events and the perfect post-procedural antithrombotic management is still under investigation. The mechanisms leading to left atrial device-related thrombus and thromboembolic complications are not fully understood. Biomarkers of coagulation activation are elevated following percutaneous device placement, peaking within one month and returning to baseline values after three months. By contrast, platelet reactivity shows no post-procedural increase. This suggests that an optimal antithrombotic regimen should perhaps include (oral) anticoagulation therapy rather than the currently more frequently prescribed antiplatelet-based regimen. Furthermore, biomarkers of endothelial activation, fibrinolysis, and on-treatment platelet reactivity may be of value in predicting device-related thrombus and bleeding and guide future medical strategy, facilitating personalized medicine.
No takes yet. Share an insight, caveat, or question.
Aarnink et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: